Abstract: A process for continuous production of C2-C4-monoalkanolamines by reaction of a corresponding C2-C4-alkylene oxide with a molar excess of ammonia (NH3), wherein aqueous ammonia is employed, in the liquid phase and in the presence of an acidic cation exchanger as catalyst which contains a crosslinked copolymer comprising acidic functional groups as the carrier matrix, wherein the cation exchanger has a total exchange capacity of not less than 1.8 eq/L.

Abstract: A method of reducing color in an alkanolamine is described. The method includes contacting the alkanolamine with a color-reducing amount of a borane complex effective to provide a color-reduced alkanolamine composition having a Platinum-Cobalt Color Value, according to Test Method ASTM D1209, of less than 50.

Abstract: The present invention relates to a process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.

Abstract: The present invention relates to a method for synthesizing artepillin C and a synthetic method for synthesizing an intermediate compound for use in preparing artepillin C. The structural formula of artepillin C is shown in the following formula (IV), and the intermediate compound is shown in the following formula (II). The synthesis method includes the following steps: a first reaction step: in the presence of a base initiator, a compound A shown in formula I and 3,3-dimethylallyl bromide are mixed, the reaction continues for a first reaction time and is stopped to generate an intermediate of artepillin C shown in formula II; and a second reaction step: the intermediate of artepillin C is dissolved in an aqueous alcohol solution and then mixed with an alkali metal salt, and the reaction continues for a second reaction time to generate artepillin C.

Abstract: The present invention relates to a method for purification of liquid compositions containing at least one sphingolipid and the use of a specific clay mineral for the purification of such liquid compositions.

Abstract: The instant invention describes hydrazide-containing compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.

Abstract: A cationic surfactant and a method of making the cationic surfactant are described. The method comprises reacting a lipophilic bio-based material having at least one epoxy functional group and a hydrophilic organic compound having at least one cationic functional group and at least one hydroxyl functional group to form a reaction product containing a stable ether linkage connecting the lipophilic bio-based material to the organic compound. At least a portion of the cationic functional groups is neutralized or ion exchanged with an organic acid. Incorporation of the simple organic acid reduces the surfactant's aquatic toxicity and acts as a substrate to encourage co-digestion of the surfactant molecule, making the compound more biodegradable.

Abstract: Amines and amine derivatives that improve the buffering range, and/or reduce the chelation and other negative interactions of the buffer and the system to be buffered. The reaction of amines or polyamines with various molecules to form polyamines with differing pKa's will extend the buffering range, derivatives that result in polyamines that have the same pKa yields a greater buffering capacity. Derivatives that result in zwitterionic buffers improve yield by allowing a greater range of stability.

Abstract: The invention provides a method for synthesizing a compound of formula wherein each R independently represents an optionally substituted aryl, heteroaryl, alkyl, perfluoroalkyl, cycloalkyl, alkoxy, aryloxy, acyl, carboxyl, hydroxyl, halogen, amino, nitro, cyano, sulfo or sulfhydryl group, in ortho, meta or para position to the cycloalkylamine moiety; R1 and R2 each independently represents a hydrogen atom, a lower alkyl group or a cycloalkyl group; R3 represents a hydrogen group, substituted aryl, heteroaryl, alkyl, perfluoroalkyl, cycloalkyl, alkoxy, aryloxy group; Y represents an oxygen atom, a sulfur atom, a NH group, a NR4 group or a CH2 group; R4 represents a hydrogen atom or an alkyl, aryl or a heteroaryl group; and n and m each independently represents an integer from 1 to 5; or a pharmaceutically acceptable salt thereof; or a precursor thereof; wherein the method comprises one or more of the following steps: (a) reacting a compound of formula (II) wherein R, R3, Y, n and m are as defined abo

Abstract: A method of reducing color in an alkanolamine, the method comprising: contacting the alkanolamine with an amount of an aqueous solution effective to provide 5 to 1000 parts per million by weight of an alkali metal borohydride, based on parts by weight of the alkanolamine; and 0.5 to 10,000 parts per million by weight of an alkali metal hydroxide, based on parts by weight of the alkanolamine; preferably wherein the color-reduced alkanolamine is not distilled after the contacting.

Abstract: The present disclosure encompasses a composition comprising three-dimensional shapes, wherein each shape consists essentially of choline chloride, and methods of making such three-dimensional shapes.

Abstract: The present invention provides a route for synthesizing monofunctional thiuram compounds that is safe, environmentally friendly, and cost effective. This method specifically involves synthesizing a monofunctional thiuram by (1) reacting a tetraorganylthiuram disulfide with an organyl mercaptan to produce the monofunctional thiuram and a dithiocarbamate metal salt or a dithiocarbamate metalloid salt under basic conditions, (2) separating the monofunctional thiuram in an organic phase from the dithiocarbamate metal salt or the dithiocarbamate metalloid salt in an aqueous phase, and (3) recovering the monofunctional thiuram from the aqueous phase. The monofunctional thiuram compounds made in accordance with this invention are of particular value as accelerators for use in the vulcanization of rubber. The use of these monofunctional thiuram compounds as accelerators provides good cure rates and as well as good scorch safety.

Abstract: The present invention relates to an N-(4-((4-(3-phenylureido)phenyl)sulfonyl)phenyl)benzenesulfonamide in the polymorphic form ?18.9, characterised by an x-ray powder diffractogram having the Bragg angles (2?/CuK?) 10.9, 11.7, 14.6, 15.0, 15.8, 16.6, 17.6, 18.9, 19.4, 20.9, 21.2, 22.0, 23.3, 24.4, 24.7, 26.1, 27.4, 29.4, 34.2, or in the polymorphic form ?21.2, characterised by an x-ray powder diffractogram having the Bragg angles (2?/CuK?) 8.7, 9.8, 10.8, 13.2, 13.9, 14.9, 15.2, 16.0, 17.4, 17.7, 18.7, 20.4, 21.2, 21.6, 22.3, 23.0, 23.3, 23.9, 24.4, 25.0, 25.8, 26.6, 28.1, 28.9, 29.4, 30.1, 30.6, 31.8, 34.5, 35.3, 35.6, 36.9, a method for production thereof, use thereof as a colour developer in a heat-sensitive recording material, and a heat-sensitive recording material comprising N-(4-((4-(3-phenylureido)phenyl)sulfonyl)phenyl)benzenesulfonamide in the polymorphic form ?18.9 or in the polymorphic form ?21.2.

Abstract: A novel promotor which contains an aniline derivative is introduced. By using the promotor alone, the time and temperature of the curing reaction of the vinyl ester resin can be controlled by the unique steric effect and electronic properties of the aniline derivative. A method for preparing the above promotor is also introduced.

Abstract: The present invention generally relates to processes for purification, recovery, and conversion of chlorophenol salts (e.g., 2,5-dichlorophenol and salts thereof). In various aspects, the present invention is related to removing one or more impurities from chlorophenol salt-containing process streams and/or recovering chlorophenol salts from process streams for use of the recovered chlorophenol elsewhere in an integrated process. Process streams that may be treated in accordance with the present invention include those incorporating one or more chlorophenol salts in a feed mixture and also those where one or more chlorophenol salts are present in a product or by-product stream of an integrated process. For example, conversion processes of the present invention are suitable as one piece of an integrated process for producing 3,6-dichloro-2-methoxybenzoic acid (dicamba) or a salt or ester thereof or a process for producing 2,4-dichlorophenoxyacetic acid (2,4-D) or a salt or ester thereof.

Abstract: The present invention provides a process for preparing 2-methyl-N-(2?-methylbutyl) butanamide of the following formula (1):the process comprising: subjecting an ?-arylethyl-2-methylbutylamine compound of the following general formula (2): wherein Ar represents a substituted or unsubstituted aryl group having 6 to 20 carbon atoms, to N-2-methylbutyrylation to form an N-?-arylethyl-2-methyl-N-(2?-methylbutyl)butanamide compound of the following general formula (3): wherein Ar is as defined above, and removing the ?-arylethyl group of the resulting compound (3) to form 2-methyl-N-(2? -methylbutyl)butanamide (1).

Abstract: The present invention relates to a crystalline form of compound 3-((L-valyl)amino)-3,3-dideuterium-1-propanesulfonic acid, preparation method and uses thereof.

Abstract: The invention relates to bis(aniline) compounds containing multiple arylethynyl, alkylethynyl, ethynyl groups or their combinations, processes of making such compounds and materials comprising such compounds. Such, bis(aniline) compounds preferably comprise multiple phenylethynyl (PE) groups, i.e. 2-4 PE moieties. Such compounds are useful monomers for the preparation of polyimides, polyamides and poly(amide-imides) whose post-fabrication crosslinking chemistry (i.e. reaction temperature) can be controlled by the number of PE per repeat unit as well as finding utility in thermosetting matrix resins, 3D printable resins, and as high-carbon-content precursors to carbon-carbon composites.

Abstract: The present invention provides a pharmaceutical composition for treating or preventing a cognitive disease or disorder, comprising a compound represented by Formula (I), an enantiomer thereof a diastereomer thereof, or a pharmaceutically acceptable salt thereof.

Abstract: A crystalline form of oxamyl is provided. The crystalline form of oxamyl is of formula (I): A crystal preparation process, the analyses of the crystal through various analytical methods, and using the crystalline form to prepare a stable agrochemical formulation is also provided. The use of various solvents towards the crystalline form preparation conditions is also provided.